Drug Trial Radar · NCT06047444
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
759
Actual
Start
Oct 12, 2023
Primary completion
May 28, 2026
Study completion Nov 12, 2026
Sponsor
- Lead sponsor
- IpsenIndustry
- Sponsor type
- Industry
- First posted
- Sep 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing chronic migraine. A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head, and is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Chronic migraine is defined as having at least 15 days of headache a month with at least 8 of those days being migraine headache days. Migraines are caused by a series of events which cause the brain to get stimulated/activated, which results in the release of chemicals that cause pain. Dysport® is a formulation of Botulinum toxin type A (BoNT-A), a medication that stops the release of these chemical messengers. The study will consist of 3 periods: 1. A 'screening period' of 6 to 12 weeks to assess whether the participant can take part to the study and requires 1 visit. 2. A first Treatment Phase of 24 weeks. On Day 1 and at Week 12 of the first Treatment Phase, participants will receive injections into various muscles across the head, neck, face and shoulders. The injections will contain either a dose "A" or dose "B" of Dysport® or a placebo (an inactive substance or treatment that looks the same as, and is given in the same way as, an active drug or intervention/treatment being studied). Participants will make 4 visits to the clinic in person and have 4 remote (online) visits. 3. A second Treatment Phase of 24 weeks (extension phase). At Week 24 and at Week 36, all participants will get Dysport® (dose "A" or dose "B"). There will be 3 in person visits and 4 remote visits. Participants will need to complete an e-diary and questionnaires throughout the study. Participants will undergo blood samplings, urine collections, physical examinations, and clinical evaluations. They may continue some other medications, but the details need to be recorded. The total study duration for a participant will be up to 60 weeks (approx. 14 months).
Conditions
- Chronic Migraine
Interventions
Botulinum toxin type ABiological
Dose "A" Unit/Injection (U/I), Intramuscular (IM) on every 12 weeks during a period of 36 weeks with a total of 4 injections.
Botulinum toxin type ABiological
Dose "B" U/I, IM on every 12 weeks during a period of 36 weeks with a total of 4 injections.
PlaceboOther
"0" U/I, IM on Day 1 and Week 12 with a total of 2 injections.
Botulinum toxin type ABiological
Dose "A" U/I, IM at Week 24 and Week 36 with a total of 2 injections.
Botulinum toxin type ABiological
Dose "B" U/I, IM at Week 24 and Week 36 with a total of 2 injections.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline at week 24 in monthly migraine days (MMD)Time frame: Every 4 weeks from Week 4 (Weeks 1-4) to Week 24 (Weeks 21-24)
Locations
120 sites in 9 countries. Site status is shown where the registry gives one.
Central Research Associates
Birmingham, Alabama
CCT Research
Phoenix, Arizona
HonorHealth Neurology
Scottsdale, Arizona
Hope Clinical Research, LLC
Canoga Park, California
Axiom Research LLC
Colton, California
Fullerton Neurological Center
Fullerton, California
Neurology Center of North Orange County
Fullerton, California
The Los Angeles Headache Center
Los Angeles, California
SDS Clinical Trials
Orange, California
840011
Palo Alto, California
Stanford University School of Medicine - Stanford Cardiovascular Institute (CVI)
Palo Alto, California
Alliance Clinical San Diego (Acclaim Clinical Research)
San Diego, California
University of Colorado Hospital - Neurology Clinic
Aurora, Colorado
Yale University School of Medicine
East Hartford, Connecticut
Hasbani Neurology
New Haven, Connecticut
New England Institute for Neurology and Headache (NEINH)/Medical Practice
Stamford, Connecticut
Visionary Investigators Network (VIN)
Aventura, Florida
Velocity Clinical Research - Hallandale Beach
Hallandale, Florida
AGA Clinical Trials
Hialeah, Florida
Infinity Clinical Research, LLC
Hollywood, Florida
Neurology Clinical Research, Inc.
Hollywood, Florida
Clinical Neuroscience Solutions Healthcare, Inc (CNS Healthcare, INC)
Jacksonville, Florida
University of Miami Leonard M. Miller School of Medicine - Professional Arts Center
Miami, Florida
Quantum Clinical Trials
Miami Beach, Florida
Clinical Neuroscience Solutions, Inc ((CNS Healthcare) - Psychiatry)
Orlando, Florida
Guardian Angel Research Center
Tampa, Florida
USF Health-Morsani Center
Tampa, Florida
Conquest Research
Winter Park, Florida
Headache Wellness Center
Greensboro, Georgia
Cedar Crosse Research Center
Chicago, Illinois
Chicago Headache Center & Research
Chicago, Illinois
Robbins Headache Clinic
Riverwoods, Illinois
MD Fort Wayne Neurological Center
Fort Wayne, Indiana
Comprehensive Neurology Services
Frederick, Maryland
Boston Clinical Trials Inc
Boston, Massachusetts
Beth Israel Deaconess Medical Center - Arnold Pain Management
Brookline, Massachusetts
Neurology Center of NE,PC - Neurology
Foxborough, Massachusetts
Mass Institute of Clinical Research
Westborough, Massachusetts
New England Regional Headache Center, Inc.
Worcester, Massachusetts
Quest Research Institute
Farmington Hills, Michigan
Showing 40 of 120 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.